0,1,2,3,4,5,6
Table 7.4:  First line immune checkpoint inhibitor combination trials for clear-cell RCC,,,,,,
Study,N,"Experimental 
arm","Primary 
endpoint","Risk 
groups","PFS (mo)
Median (95% CI)
HR","OS (mo)
Median (95% CI)
HR"
"KEYNOTE-426
NCT02853331
Median 
follow-up 
42.8 months
[523, 524, 530]",861,"PEMBRO  
200 mg. IV Q3W 
plus AXI 5 mg.  
PO BID
vs.
SUN 50 mg  
PO QD 4/2 wk","PFS and OS 
in the ITT by 
BICR","IMDC
FAV     31%
IMD     56%
POOR 13%
MSKCC
Not 
determined","(ITT)
PEMBRO + AXI: 
15.7 (13.6–20.2)
SUN: 11.1 (8.9–12.5)
HR: 0.68 
(95% CI: 0.58–0.80)
p < 0.0001","(ITT)
PEMBRO + AXI: 
45.7 (43.6–NR)
SUN: 40.1  
(34.3–44.2)
HR: 0.73 
(95% CI: 0.60–0.88)
p = 0.001"
"JAVELIN 101 
NCT02684006
Median 
follow-up 
19 months
[457, 528]",886,"AVE 10 mg/kg  
IV Q2W plus  
AXI, 5 mg  
PO BID
vs.
SUN 50 mg  
PO QD 4/2 wk","PFS in the 
PD-L1+ 
population 
and OS in 
the ITT by 
BICR","IMDC
FAV     22%
IMD     62%
POOR 16%
MSKCC
FAV     23%
IMD     66%
POOR 12%","(PD-L1+)
AVE + AXI: 
13.8 (10.1–20.7)
SUN: 7.0 (5.7–9.6)
HR: 0.62 
(95% CI: 0.49–0.78)
p < 0.0001","(PD-L1+)
AVE + AXI: NR
SUN: 28.6 (27.4–NE)
HR: 0.83 
(95% CI: 0.60–1.15)
p = 0.1301"
"IMmotion151
NCT02420821
Median 
follow-up 
24 months
[509, 529]",915,"ATEZO 
1200 mg fixed 
dose IV plus  
BEV 15 mg/kg  
IV on days 1 and 
22 of each 42-day 
cycle
vs.
SUN 50 mg
PO QD 4/2 wk","PFS in the 
PD-L1+ 
population 
and OS in 
the ITT by 
IR","IMDC
Not 
determined
MSKCC
FAV     20%
IMD     69%
POOR 12%","(PD-L1+)
ATEZO + BEV: 
11.2 (8.9–15.0)
SUN: 7.7 (6.8–9.7)
HR: 0.74 
(95% CI: 0.57–0.96)
p = 0.0217","(ITT)
ATEZO + BEV: 
36.1 (31.5–42.3)
SUN: 35.3  
(28.6–42.1NE)
HR: 0.91 
(95% CI: 0.76–1.08)
p = 0.27"
"Checkmate 
214
NCT02231749
Median 
follow-up of 
60 months
[455, 522]",1096,"NIVO 3 mg/kg 
plus 
IPI 1 mg/kg IV 
Q3W for 4 doses 
then NIVO 
3 mg/kg IV Q2W
vs.
SUN 50 mg  
PO QD 4/2 wk","PFS and 
OS in the 
IMDC inter-
mediate and 
poor risk 
population 
by BICR","IMDC
FAV      23%
IMD      61%
POOR  17%
MSKCC
Not 
determined","(IMDC IMD/poor)
NIVO + IPI: 
11.6 (8.4–16.5)
SUN: 8.3 (7.0–10.4)
HR: 0.73 
(95% CI: 0.61–0.87)","(IMDC IMD/poor)
NIVO + IPI: 
47.0 (35.4–57.4)
SUN: 
26.6 (22.1–33.5)
HR: 0.68 
(0.58–0.81)
p < 0.0001"
"CheckMate 
9ER 
NCT03141177
Median 
follow-up of 
23.5 months
[525, 526]",651,"NIVO 240 mg 
fixed dose IV 
every 2 wk plus 
CABO 40 mg 
PO daily 
vs.
SUN 50 mg  
PO QD 4/2 wk","PFS in the 
ITT by BICR","IMDC
FAV      22%
IMD      58%
POOR  20%
MSKCC
Not 
determined","(ITT)
NIVO + CABO: 
17.0 (12.6–19.4)
SUN: 8.3 (6.9–9.7)
HR: 0.52 
(95% CI: 0.43–0.64)
p < 0.0001","(ITT)
NIVO + CABO:  
NR (NE)
SUN: 29.5 (28.4–NE)
HR: 0.66 
(98.9% CI: 0.50–
0.87)
p = 0.0034"
"CLEAR
NCT02811861
Median  
follow-up of  
33.4 months
[527, 531]",712,"PEMBRO  
200 mg IV Q3W 
plus LEN 20 mg 
PO QD
vs.
SUN 50 mg  
PO QD 4/2 wk","PFS in the 
ITT by BIRC","IMDC
FAV     31%
IMD     59%
POOR   9%
NE         1%
MSKCC
FAV     27%
IMD     64%
POOR   9%","(ITT)
PEMBRO + LEN: 
23.9 (20.8–27.7)
SUN: 9.2 (6.0–11.0)
HR: 0.39 
(95% CI: 0.32–0.49) 
p > 0.001","H
(ITT)
PEMBRO + LEN:  
NR (41.5–NE)
SUN: NR (38.4–E)
R: 0.72 
(95% CI: 0.55–0.93)  
p = 0.005"
"COSMIC-313
Median  
follow-up of  
20.2 months
[521]",855,"NIVO 3 mg/kg 
plus IPI 1 mg/kg  
IV Q3W for 4 
doses then  
NIVO 3 mg/kg  
IV Q2W +  
CABO 40 mg  
PO QD
vs. NIVO 3 mg/kg  
plus IPI 1 mg/kg  
IV Q3W for 4 
doses then  
NIVO 3 mg/kg  
IV Q2W","PFS in 
the PITT 
population 
(first 
550 pts. 
randomised)","IMDC
IMD     75%
POOR  25%","(PITT)
NIVO + IPI + CABO: 
NR (14.0–NE)
NIVO + IPI:  
11.3 (7.7–18.2)
HR: 0.73 (95%  
CI: 0.57–0.94)  
p = 0.013",NR
